Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Søk Study Connect
  • NCT05543629

Active, Not Recruiting

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer - CA115-001

Oppdatert: 8 april, 2024   |   ClinicalTrials.gov

Utskriftsvennlig Sammendrag

VURDERER DU DENNE STUDIEN?
Skriv ut denne siden og studieveiledningen for å hjelpe deg å snakke med legen din.
Bruk Veiledning for studiedeltakere til å navigere gjennom deltakerprosessen i en klinisk studie. Forstå viktige faktorer å vurdere før du bestemmer deg og motta spørsmål som du kan stille til helsepersonalet ditt.
Skriv ut denne siden CA115-001
Last ned Veiledning for studiedeltakere

VELG SPRÅK

Vis detaljer

  • Phase 1/Phase 2

    Fase

  • Kjønn

  • 18+

    Aldersgruppe

  • Active, Not Recruiting

Behandlingsalternativer

Studiearmer
TILDELT INTERVENSJON
Experimental: Part A: BMS-986442 + Nivolumab
Biological: Nivolumab, BMS-986442
Experimental: Part B1: BMS-986442 + Nivolumab
Biological: Nivolumab, BMS-986442
Experimental: Part B2: BMS-986442 + Nivolumab
Biological: Nivolumab, BMS-986442
Experimental: Part C: BMS-986442 + Nivolumab + Docetaxel
Biological: BMS-986442, Nivolumab Drug: Docetaxel
Experimental: Part D: BMS-986442 + Nivolumab + Carboplatin + Pemetrexed
Biological: BMS-986442, Nivolumab Drug: Pemexetred, Carboplatin
Experimental: Part E: BMS-986442 + Nivolumab + Carboplatin + Paclitaxel
Biological: BMS-986442, Nivolumab Drug: Paclitaxel, Carboplatin

Nøkkelkriterier for kvalifikasjon

Inclusion Criteria: - Participants in all parts of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. - Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. - Participants must have a life expectancy of at least 3 months at the time of first dose. Exclusion Criteria: - Untreated symptomatic central nervous system metastases or leptomeningeal metastases. - Concurrent malignancy (present during screening) requiring treatment, or history of prior malignancy active within 2 years prior to randomization in study Part B1 or treatment assignment in all other study parts. - Participants with an active, known, or suspected autoimmune disease. Other protocol-defined inclusion/exclusion criteria apply.

Vi anbefaler at du kontakter BMS for å rapportere bivirkninger.
Bivirkninger (uønskede hendelser) og andre rapporterbare hendelser er definert her
For å rapportere bivirkninger (uønskede hendelser) eller reklamere på et legemiddel: Medisinsk informasjon

MLTNO2000046